登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Siglec-2 >SI2-HF2H6

FITC-Labeled Human Siglec-2 / CD22 Protein, His Tag

分子别名(Synonym)

CD22,SIGLEC2,BL-CAM,SIGLEC-2,Siglec2,SIGLEC2FLJ22814

表达区间及表达系统(Source)

FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6) is expressed from human HEK293 cells. It contains AA Asp 20 - Arg 687 (Accession # P20273-1). It is the FITC labeled form of Human Siglec-2, His Tag (Cat. No. CD2-H52H8).

Predicted N-terminus: Asp 20

Request for sequence

蛋白结构(Molecular Characterization)

Siglec-2 Structure

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 77.0 kDa. The protein migrates as 100-120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

偶联(Conjugate)

FITC

Excitation source: 488 nm spectral line, argon-ion laser

Excitation Wavelength: 488 nm

Emission Wavelength: 535 nm

标记(Labeling)

The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

蛋白标记度(Protein Ratio)

The FITC to protein molar ratio is 3-5.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Siglec-2 SDS-PAGE

FITC-Labeled Human Siglec-2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Siglec-2 ELISA

Immobilized Monoclonal Anti-Human CD22 Antibody, Human IgG1 at 10 μg/mL (100 μL/well) can bind FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6) with a linear range of 0.078-20 μg/mL (QC tested).

Protocol

 

CAR阳性表达率检测(Evaluation of CAR expression)

FACS Analysis of Anti-CD22 CAR Expression

Siglec-2 CAR_T

293 cells were transfected with anti-CD22-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6, 10 µg/mL) and C. FITC-labeled Protein Control. A. Non-transfected 293 cells and C. FITC-labeled Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD22-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6) (QC tested).

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

B-cell receptor CD22 is also known as Sialic acid-binding Ig-like lectin 2 (Siglec-2), B-lymphocyte cell adhesion molecule (BL-CAM), T-cell surface antigen Leu-14, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. CD22 mediates B-cell B-cell interactions, and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2 / CD22 binds sialylated glycoproteins, one of which is CD45. Siglec2 / CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

 

前沿进展

[Construction of a camel-derived natural phage nanobody display library and screening of anti-CD22 nanobodies]
He, Cui, Zhang et al
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2025) 41 (3), 254-261
Abstract: Objective To screen the anti-CD22-specific nanobodies to provide a basis for immunotherapy agents. Methods The naive phage nanobody library was constructed and its diversity was analyzed. Three rounds of biotinylated streptavidin liquid phase screening were performed by using biotinylated CD22 antigen as the target, and the sequence of nanobodies against CD22 were identified by ELISA and gene sequencing. Results The capacity of the constructed naive phage nanobody library was 3.89×109 CFU/mL, and the insertion of effective fragments was higher than 85%. Based on this library, seven anti-human CD22 nanobodies were screened, and the amino acid sequence comparison results showed that the overall similarity was 70.34%, and all of them were hydrophilic proteins. The results of protein-protein complex docking prediction showed that the mimetic proteins of the five nanobody sequences could be paired and linked to CD22, and the main forces were hydrophobic interaction and hydrogen bonding. Conclusion This study provided a basis for the study of chimeric antigen receptor T cells targeting CD22, successfully constructed the natural phage nanobody library and obtaining five anti-CD22-specific nanobodies.
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia
Papayannidis, Petracci, Zappasodi et al
Cancer (2025) 131 (7), e35820
Abstract: Inotuzumab ozogamicin (IO) has helped to change the treatment paradigm in B-cell acute lymphoblastic leukemia (B-ALL) but real-world data are limited.The INO-CD22 study is a multicenter retrospective cohort study of adult patients with relapsed/refractory B-ALL treated with IO in 24 Italian centers from 2014 to 2019, with the aim of assessing the response, survival, and toxicity of IO.Data for 73 eligible patients were obtained: the median age at the start of IO treatment was 52.7 years (I-III quartiles, 51.9-53.5 years), the median number of previous lines was three (I-III quartiles, two to four), and prior exposure to induction standard chemotherapy and blinatumomab occurred in 85% and 57.5% of cases, respectively. IO was administered following the label schedule. A 74.0% overall response rate was achieved, with a 69.8% complete remission rate and a 4.1% complete remission with incomplete hematologic reconstitution rate. The median duration of response was 4.4 months (I-III quartiles, 2.3-11.2 months). With a median follow-up of 37.2 months, the median overall survival (OS) was 7.9 months (95% CI, 6.08-12.42 months) with a 3- and 5-year OS of 21.2% (95% CI, 11.9%-32.3%) and 5.3% (95% CI, 9.6%-29.8%), respectively. Overall, 37% of patients were able to proceed to allogeneic hematopoietic stem cell transplantation. Eight patients (11.0%) experienced veno-occlusive disease/sinusoidal obstruction syndrome; the most frequent grade ≥3 nonhematologic adverse events were liver toxicities and pneumonia (two grade 4 and one grade 5, respectively).Despite the limitations of retrospective studies, the INO-CD22 study highlights the favorable safety profile and clinical activity of IO within a real-world context.© 2025 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL
Wang, Huang, Jiang et al
Cancer Immunol Immunother (2025) 74 (5), 156
Abstract: Chimeric antigen receptor (CAR) T-cell infusion (CTI) therapy has emerged as a breakthrough therapy in relapsed/refractory B-cell non-Hodgkin's lymphoma (R/R B-NHL), but a substantial number of patients still suffer treatment failure. Data on disease history, subsequent salvage therapies, and outcomes of patients who face treatment failure after the first CTI (CTI1) have not been reported in detail or systematically studied. Here, a retrospective analysis was performed on a total of 61 R/R B-NHL patients in whom salvage therapies were adopted after CTI1 treatment failure, with their clinical characteristics, subsequent management and outcomes described in detail. The results suggested that second-time CTI (CTI2) used as salvage therapy after failure of CTI1 could achieve a better transient overall response rate (ORR) than other salvage treatments (non-CTI2) in only a minority of patients (8/27 vs. 2/34, P=0.014). Nevertheless, the non-CTI2 group showed better event-free survival (EFS) (P = 0.007) and overall survival (OS) (P = 0.048) than the CTI2 group, with a median follow-up of 6.7 months vs. 4.7 months. In addition, univariate and multivariate analyses showed that only the status of the tumor at disease onset was an independent risk factor for survival; salvage therapy after CTI1 treatment failure was not. The adverse effects of CTI2 treatment were generally similar to those of non-CTI2 treatment, but the infection-related mortality was considerably higher. In conclusion, the prognosis of patients who fail CTI1 therapy is very poor regardless of the subsequent salvage therapies, and clinicians should be cautious about adopting CTI2 treatment after failure of treatment with the CD19/22 cocktail CTI1 in R/R B-NHL. Large-scale prospective studies are warranted, and new strategies are urgently needed to prevent treatment failure and improve the survival of B-cell lymphoma patients in future.© 2025. The Author(s).
Insights into the transcriptional regulation of CD22 in B cell chronic lymphocytic leukemia
Enkhbayar, Lu, Tsai et al
J Biol Chem (2025)
Abstract: CD22 (also known as Siglec-2) is a member of the Siglec family of glycan-recognition proteins and functions as a negative regulator of the B-cell receptor-mediated calcium signaling. Although the low level of CD22 expression on the B cells in patients with chronic lymphocytic leukemia (CLL) has been documented, CD22's role and its down-regulation mechanism in CLL are yet to be fully studied. In this study, we confirmed that the surface CD22 protein and its mRNA are down-regulated in the B cells of CLL patients. We analyzed a public transcriptomic dataset and found that the CD22 mRNA level is negatively associated with the prognosis of patients with CLL. To investigate the mechanism of CD22 down-regulation, we characterized the minimal promoter of the human CD22 gene required for its transcriptional activation in B cell lines. We employed an unbiased proteomic approach to identify several transcription factors binding to the minimal CD22 promoter, including PU.1, Spi-B, and IRF4. The chromatin immunoprecipitation-quantitative PCR revealed that PU.1 was enriched in a CD22-high cell line, while IRF4 was enriched in a CD22-low cell line. We then conducted over-expression/knockout/knockdown experiments, which validated that PU.1 and Spi-B positively, and IRF4 negatively, regulate CD22 transcription. Our study thus provides insights into the transcriptional regulation of CD22 and the mechanism by which CD22 expression is down-regulated in the B cells of patients with CLL.Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Showing 1-4 of 1042 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Siglec-2靶点信息
英文全称:CD22
中文全称:CD22
种类:Homo sapiens
上市药物数量:2详情
临床药物数量:61详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定